To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers

Inclusion Criteria: * Healthy, male or female subjects age 18 to 45 years of age (inclusive) * In good health * Female subjects either surgically sterilized at least 6 months prior to study participation or post-menopausal (no regular menstrual bleeding for at least 2 years) * Body mass index within the range of 18.5 to 28 kg/m2 and weigh at least 45 kg Exclusion Criteria: * Smokers * Use prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements, potassium supplements) within 2 weeks prior to dosing. Paracetamol is acceptable * Participation in any clinical investigation within 4 weeks prior to dosing * Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing * Significant illness within 2 weeks prior to dosing. * History of clinically significant cardiac abnormalities, fainting, low blood pressure upon standing, irregular heartbeats. * History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or untreated). * History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). * Known hypersensitivity or severe reaction to valsartan or similar drugs * Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study. * History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result. * A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. * History of drug or alcohol abuse within the 6 months prior to dosing Other protocol-defined inclusion/exclusion criteria may apply